+390677209020 | +39 0267380552 info@direnzo.biz | sedemilano@direnzo.biz | Italian Language

Biocidal product and ECHA: New draft for the Guideline on Substances of Concern (SoC)

Based on the guidance already presented by the European Commission during the meetings of the Competent Authority, CA, (CA-Sept25-Doc.4.5-CA-Nov14-Doc.5.11-SoC guidance_finalrev1) the European Chemicals Agency (ECHA) has published a new draft of a guideline totally dedicated to the identification and assessment of the so called Substances of Concern (SoC), within the framework of the Biocidal Products Regulation, EU no. 528 of 2012 (BPR).

An important moment for chemical industry

This publication is an important tool for the whole chemical and manufacturing industry, and intends to outline an applicative interpretation of the SoC definition, already present in the BPR regulation under article 3(1) (f), in order to eliminate any uncertainty regarding the identification and classification of a “non-active” substance (co-formulant) as SoC within a biocidal formulation, that has existed over the years, between applicants as well as competent authorities of Member States.

The management of hazardous co-formulants included among biocidal products has always required a relevant analytical accuracy, but the new guideline is trying to standardise procedures at Community level, imposing a deep review of companies’ portfolios.

To understand the extent of this novelty, the very concept of substance of concern must be contextualised within the European legal framework.

What is a substance of concern?

According to article 3 of the Biocidal Products Regulation, a substance of concern is defined as any substance, other than the active substance, which has an inherent capacity to cause an adverse effect, immediately or in the more distant future, on humans, animals or the environment and is present or is produced in a biocidal product in sufficient concentration to present risks.

Until today, the criteria to establish when a co-formulant should be considered as such and how a relevant assessment of its toxicological and ecotoxicological risk should be carried out were fragmented in several guidance documents and decisions by technical committees.

The current initiative of the European Chemicals Agency aims at grouping, updating and making binding these operational methods in a single official reference text.

Whom is the regulation addressed to?

The draft submitted by ECHA bilaterally addresses the two main stakeholders of the regulatory market. On one side, there are chemical companies and authorisation holders that must prepare registration dossiers and demonstrate the safety and efficacy of their own formulations; on the other, there are competent national authorities that have the task of assessing the conformity of these dossiers before granting marketing authorisations.

The harmonisation of the guidelines has the goal of sensibly reducing the discrepancies found in the opinions of the various Member States, an event that in the past has often slowed down the procedures for the mutual recognition of national authorisations, creating bureaucratic barriers and market asymmetries.

The timelime

The timeline established by the European Chemicals Agency for the final adoption of this document is structured in order to ensure the maximum participation of industrial and institutional stakeholders.

The current phase provides for the direct involvement of technical experts from the working groups of the Biocidal Products Committee (BPC), along with the representatives of the trade associations accredited at European level. These subjects will have the whole summer for a thorough examination of the text, to evaluate its technical and economic impact and to send their official comments.

This consultation process is essential to refine the guidelines and make them applicable to complex industrial realities without compromising the primary goal of protecting public health and the ecosystem.

Then, the agency will collect and examine the feedbacks received to draft the final text, whose official publication has already been scheduled in July 2027. Companies have therefore a well-defined time frame to start the investigation of their own formulation and plan any required investment.

Which implications for manufacturers?

There could be far-reaching practical implications for enterprises that manufacture or market biocidal products, in case additional studies are requested along with the existing ones. The identification of a substance of concern in a formulation does not automatically imply a ban for its use, but it imposes the obligation to carry out a detailed risk assessment for each expected use scenario. 

If this assessment shows that the risk for either human health – especially for vulnerable groups such as children or health operators – or for the environment is not acceptable, the authorities can impose severe use restrictions or deny the product authorisation.

Moreover, the presence of these substances directly affects the classification and the finished product according to the CLP (Classification, Labelling and Packaging) Regulation, making any communication about the hazard more complex along the supply chain and conditioning consumers’ and professional users’ purchasing choices.

Clear use criteria

Another crucial aspect addressed by the guideline is the interconnection between the Biocidal Products Regulation (BPR) and the REACH Regulation. Many of the substances qualifying as of concern in biocides are already included in the Candidate List of the substances of very high concern (SVHC) or are subject to restrictions and authorisations according to the REACH.

The new guideline of the Agency establishes clear criteria for the use of the data generated within the REACH in order to avoid duplicates in the scientific tests, promoting at the same time an approach directed to reduce experiments on vertebrates. This requires a very strong internal synergy inside companies between R&D and RA, that must be able to map the origin and the toxicologic profile of each single starting material used with pinpoint accuracy. 

Our regulatory support

In this context of deep transition and increased scientific strictness, Di Renzo Regulatory Affairs can be the ideal strategic partner supporting companies in the chemical sector (and other related products such as cosmetics, drugs, etc.) in their harmonisation with the new European directives.

Thanks to a multidisciplinary team made of chemists and regulatory affairs experts with a consolidated experience with the Biocidal Products Regulations (BPR), our company is able to offer a full and custom-made consulting service. We carry out in-depth controls on the products to promptly identify the presence of potential substances of concern (SoC) in the preparations, assessing the impact of the future guidelines on the corporate compliance.

Moreover, Di Renzo Regulatory Affairs manages the whole documental transition toward the requirements becoming effective in 2027, taking care, with the cooperation of outer professionals, of planning any alternative tests, carrying out advanced risk assessments, and addressing ECHA and national competent authorities directly, ensuring business continuity for enterprises and maintaining their competitiveness in the European market.

Written on 06/07/2026 by Clara Cisternino and Giorgia Martini